Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Imatinib

Imatinib Phase 3 dose trials (combined analysis on label)

Novartis · Phase 3 · Completed · Enrollment 1640

Registry id n/r

ArmPopulationDoseEstimandComparatorEfficacy
Imatinib 400 mg dailyunresectable or metastatic KIT (CD117) positive GIST400 mgITTn/rmedian progression-free survival: 18.9 months, median follow up 37.5 monthsmedian overall survival: 49 months, median follow up 37.5 monthsbest overall response (complete 5.3% plus partial 46.1%): 51.4%, combined analysis, Sum of label complete response 43 (5.3%) and partial response 377 (46.1%)
Imatinib 800 mg dailyunresectable or metastatic KIT (CD117) positive GIST800 mgITTimatinib 400 mgmedian progression-free survival: 23.2 months, median follow up 37.5 monthsmedian overall survival: 48.7 months, median follow up 37.5 months